AR115106A1 - CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS - Google Patents
CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICSInfo
- Publication number
- AR115106A1 AR115106A1 ARP190101309A ARP190101309A AR115106A1 AR 115106 A1 AR115106 A1 AR 115106A1 AR P190101309 A ARP190101309 A AR P190101309A AR P190101309 A ARP190101309 A AR P190101309A AR 115106 A1 AR115106 A1 AR 115106A1
- Authority
- AR
- Argentina
- Prior art keywords
- therapeutics
- effectiveness
- enhancing
- treatment method
- cancer treatment
- Prior art date
Links
Abstract
Reivindicación 1: Un método para tratar un cáncer en un sujeto, que comprende administrar una cantidad terapéuticamente eficaz de un anticuerpo biespecífico BCMAxCD3 al sujeto para tratar el cáncer, en donde el sujeto es recidivante o refractario al tratamiento con una terapéutica anterior contra el cáncer. Reivindicación 4: El método de una cualquiera de las reivindicaciones 1 - 3, en donde el anticuerpo biespecífico BCMAXCD3 es un isotipo lgG4 y comprende fenilalanina en la posición 405 y arginina en la posición 409 en la HC1 y leucina en la posición 405 y lisina en la posición 409 en la HC2, en donde la numeración de residuos es de acuerdo con el índice de la UE.Claim 1: A method of treating cancer in a subject, comprising administering a therapeutically effective amount of a bispecific BCMAxCD3 antibody to the subject to treat the cancer, wherein the subject is relapsed or refractory to treatment with prior cancer therapeutics. Claim 4: The method of any one of claims 1-3, wherein the bispecific antibody BCMAXCD3 is an IgG4 isotype and comprises phenylalanine at position 405 and arginine at position 409 at HC1 and leucine at position 405 and lysine at position 409 in HC2, where the waste numbering is in accordance with the EU index.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862672222P | 2018-05-16 | 2018-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR115106A1 true AR115106A1 (en) | 2020-11-25 |
Family
ID=73543388
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101309A AR115106A1 (en) | 2018-05-16 | 2019-05-16 | CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS |
ARP190101310A AR115107A1 (en) | 2018-05-16 | 2019-05-16 | CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101310A AR115107A1 (en) | 2018-05-16 | 2019-05-16 | CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS |
Country Status (1)
Country | Link |
---|---|
AR (2) | AR115106A1 (en) |
-
2019
- 2019-05-16 AR ARP190101309A patent/AR115106A1/en unknown
- 2019-05-16 AR ARP190101310A patent/AR115107A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR115107A1 (en) | 2020-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002945A1 (en) | Methods for treating cancers and enhancing the efficacy of t-cell redirection therapeutics | |
AR110203A1 (en) | ANTI-TIM-3 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES | |
AR109605A2 (en) | METHOD FOR TREATING PERIPHERAL VASCULAR DISEASES, COMPOSITION AND USE | |
PH12021500001A1 (en) | Antibodies that target hiv gp120 and methods of use | |
HRP20231156T1 (en) | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer | |
MX2021008888A (en) | Humanized anti-tau antibodies. | |
RU2018123717A (en) | COMBINED TREATMENTS, THEIR APPLICATIONS AND METHODS | |
EA201070740A1 (en) | METHOD OF TREATING BONE FRACTURE WITH ANTIBODIES AGAINST SKLEROSTIN | |
EA201891495A1 (en) | BISPECIFIC ANTI-CD20 / ANTI-CD3 ANTIBODIES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA | |
MX2023008453A (en) | Methods of treating substance abuse. | |
AR077595A1 (en) | COMBINATION TREATMENTS | |
AR101740A1 (en) | COMBINATION AND COMPOSITION THERAPY | |
BR112018002436A2 (en) | combination treatment of methods uses of these | |
EA201890878A1 (en) | METHOD OF TREATMENT OF MEDDALLOBLASTOMES USING EZH2 INHIBITOR | |
EA202192528A1 (en) | COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS TO IMPROVE EFFICIENCY IN CANCER TREATMENT | |
AU2017293423A8 (en) | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer | |
CL2019001749A1 (en) | Use of anti-sclerostin antibodies in the treatment of imperfect osteogenesis. | |
AR086984A1 (en) | ANTI-CXCR4 ANTIBODY WITH EFFECTIVE FUNCTIONS AND ITS USE IN CANCER TREATMENT | |
MX2021007330A (en) | Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor. | |
CR20210514A (en) | Use of reboxetine to treat narcolepsy | |
AR124639A1 (en) | COMPOSITION FOR THE TREATMENT OF A VASCULAR DISEASE, THE PREVENTION OF A VASCULAR DISEASE, THE TREATMENT OF HYPERTENSION, OR THE PREVENTION OF HYPERTENSION | |
CO2023017973A2 (en) | Transforming Growth Factor βeta Ligand Traps for Disease Treatment | |
AR115106A1 (en) | CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS | |
PE20221039A1 (en) | METHODS FOR USING ANTI-CD79b IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | |
MX2021006654A (en) | Use of cocculus hirsutus extract for treating dengue. |